Skip to main content
Journal cover image

98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study

Publication ,  Conference
Ahn, E; Rothe, M; Mangat, PK; Garrett-Mayer, E; Al Baghdadi, T; Baron, AD; Krauss, JC; Balmanoukian, AS; Bauman, JR; Hameed, MK; Mileham, KF ...
Published in: Annals of Oncology
September 2022

Duke Scholars

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2022

Volume

33

Start / End Page

S583 / S584

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ahn, E., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Al Baghdadi, T., Baron, A. D., … Schilsky, R. L. (2022). 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study. In Annals of Oncology (Vol. 33, pp. S583–S584). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.130
Ahn, E., M. Rothe, P. K. Mangat, E. Garrett-Mayer, T. Al Baghdadi, A. D. Baron, J. C. Krauss, et al. “98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study.” In Annals of Oncology, 33:S583–84. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.130.
Ahn E, Rothe M, Mangat PK, Garrett-Mayer E, Al Baghdadi T, Baron AD, et al. 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study. In: Annals of Oncology. Elsevier BV; 2022. p. S583–4.
Ahn, E., et al. “98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S583–84. Crossref, doi:10.1016/j.annonc.2022.07.130.
Ahn E, Rothe M, Mangat PK, Garrett-Mayer E, Al Baghdadi T, Baron AD, Krauss JC, Balmanoukian AS, Bauman JR, Hameed MK, Mileham KF, Thota R, Gold PJ, Meric-Bernstam F, Powell SF, Yang ES, O’Lone R, Grantham GN, Halabi S, Schilsky RL. 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study. Annals of Oncology. Elsevier BV; 2022. p. S583–S584.
Journal cover image

Published In

Annals of Oncology

DOI

ISSN

0923-7534

Publication Date

September 2022

Volume

33

Start / End Page

S583 / S584

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis